Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis
View abstract on PubMed
Summary
This summary is machine-generated.The sirolimus-eluting stent significantly reduces restenosis by 12 months, showing sustained clinical improvement. High-risk patients experienced a 70-80% reduction in restenosis with this drug-eluting stent.
Area Of Science
- Cardiology
- Interventional Cardiology
- Biomedical Engineering
Background
- Evaluating long-term efficacy of sirolimus-eluting stents (SES) in a large patient cohort.
- Assessing sustained clinical improvement beyond initial observations.
- Investigating SES performance in high-risk patient subsets prone to restenosis.
Purpose Of The Study
- To confirm sustained clinical improvement with SES at 12 months.
- To evaluate the treatment effect of SES in specific high-risk patient groups.
- To compare restenosis rates between SES and bare metal stents.
Main Methods
- A double-blind, randomized trial involving 1058 patients undergoing percutaneous coronary intervention.
- Random assignment to either sirolimus-eluting stent (533 patients) or control bare stent (525 patients).
- Assessment of clinical restenosis via target-lesion revascularization at 9 and 12 months.
Main Results
- No significant difference in procedural success or in-hospital outcomes between groups.
- Clinical restenosis at 9 months: 4.1% (SES) vs. 16.6% (bare stent) (P<0.001).
- Clinical restenosis at 12 months: 4.9% (SES) vs. 20% (bare stent) (P<0.001), with increasing absolute reduction.
- High-risk subsets (vessel size, lesion length, diabetes) showed 70-80% reduction in restenosis at 1 year.
- No differences in death or myocardial infarction rates observed.
Conclusions
- Sirolimus-eluting stent implantation leads to sustained clinical improvement at 1 year.
- Significant reduction in target-lesion revascularization (clinical restenosis) is achieved with SES.
- The absolute reduction in clinical restenosis continues to increase between 9 and 12 months.
- SES demonstrates a substantial 70-80% relative reduction in restenosis in high-risk patients at 12 months.